Toggle Nav
mobile icon
My Cart
Close
  • Menu
  • Setting
  • Home
  • Search results for: 'research area mapk mek1 2'

Search results for: 'research area mapk mek1 2'

Items 341-350 of 765

Page
per page
  1. Empagliflozin (BI 10773)
    A4601 Empagliflozin (BI 10773)
     2 Citation
    Summary: SGLT-2 inhibitor for oral treatment of type 2 diabetes
      insoluble in H2O; ≥20.75 mg/mL
  2. LUF 6283
    B5751 LUF 6283
    Summary: partial agonist of hydroxycarboxylic acid receptor 2 (HCA2)
      <16.82 mg/mL
  3. Fruquintinib(HMPL-013)
    B5864 Fruquintinib(HMPL-013)
    Target: VEGFR
    Summary: Potent and selective inhibitor of VEGFR 1, 2, 3
      insoluble in H2O; insoluble in EtOH; ≥6.35 mg/mL
  4. Dimethyl Fumarate
    B1931 Dimethyl Fumarate
    Summary: nuclear factor (erythroid-derived)-like 2 (Nrf2) pathway activator
  5. PP 3
    B7190 PP 3
    Summary: Negative control for the Src kinase inhibitor PP 2
      Soluble in DMSO
  6. MMF
    B7674 MMF
    Summary: Nuclear factor (erythroid-derived-2)-like 2 (Nrf2) pathway activator
      ≥25.2 mg/mL
  7. NSC727447
    BA1934 NSC727447
    Summary: NSC727447 is a ribonuclease H (RnaseH) inhibitor of -1 and -2.
  8. ZED-1227
    BA7771 ZED-1227
    Summary: ZED-1227 is a specific, orally active transglutaminase 2 inhibitor.
  9. Vicasinabin
    BA5214 Vicasinabin
    Summary: Vicasinabin (RG7774) is a potent agonist of cannabinoid receptor 2.
  10. TUG-1375
    BA5326 TUG-1375
    Summary: TUG-1375 is a free fatty acid receptor 2 agonist.

Items 341-350 of 765

Page
per page
Shop By
Shopping Options
Category
  1. Signaling Pathways152item
  2. Natural Products2item
  3. Amino Acids & Building Blocks1 item
  4. Protein12item
  5. Kits4item
  6. Screening Library34item
  7. Modified Nucleotides2item
  8. HyperScribe™ All in One mRNA Synthesis Kit1 item
  9. Peptides2item
  10. Molecular Biology9item
  11. Cell Biology22item
  12. Peptides & Proteins60item
  13. Protein & Immunology6item
  14. Cell culture1 item
  15. Antibody144item
  16. Biochemical Reagent329item
Specificity
  1. Selective43item
Reversibility
  1. Reversible3item
Target
  1. Cyclin-Dependent Kinases4item
  2. Histone Deacetylases (HDACs)2item
  3. Akt1 item
  4. PI3K2item
  5. Raf2item
  6. Aurora Kinases1 item
  7. EZH21 item
  8. mTOR4item
  9. MMP1 item
  10. FLT32item
  11. PLK1 item
  12. Eph Receptors1 item
  13. VEGFR9item
  14. PDGFR2item
  15. c-Kit1 item
  16. p385item
  17. PKB1 item
  18. Bcr-Abl2item
  19. MEK7item
  20. FGFR2item
  21. MET1 item
  22. Src2item
  23. Trk Receptors2item
  24. EGFR2item
  25. PD-1/PD-L1 interaction1 item
  26. JAK1 item
  27. EZH11 item
  28. DNA-PK2item
  29. DNA Methyltransferases1 item
  30. c-MET1 item
  31. PKC1 item
  32. SGLT1 item
  33. HER21 item
  34. LRRK22item
  35. Insulin and Insulin-like Receptors1 item
  36. PARP1 item
  37. ALK1 item
  38. PKG1 item
  39. PKA1 item
  40. Tie-22item
  41. ATM/ATR1 item
  42. COX1 item
  43. P1101 item
  44. Hck1 item
  45. Cytidine deaminases1 item
  46. KDR1 item
  47. Fyn kinase1 item
  48. c-Fms tyrosine kinase1 item
  49. Ftase1 item
  50. Prk1 item
  51. DCLK21 item
  52. UCP1 item
  53. SK1 item
  54. reverse transcriptase1 item
Reported Experiments
  1. Animal Experiments52item
  2. Cell Experiments43item
Related Disease
  1. Acute Myeloid Leukemia2item
  2. Adrenocortical Carcinoma1 item
  3. Biliary Cancer1 item
  4. Bladder Cancer1 item
  5. Bladder Carcinoma2item
  6. Breast Cancer12item
  7. Cancer34item
  8. Cervical Cancer1 item
  9. Cholangiocarcinoma1 item
  10. Clear Cell Renal Cell Carcinoma1 item
  11. Colon Cancer5item
  12. Colorectal Cancer6item
  13. Diabetes1 item
  14. Glioblastoma3item
  15. HIV1 item
  16. Liver Cancer1 item
  17. Lung Cancer1 item
  18. Lymphoma1 item
  19. Melanoma4item
  20. Multiple Myeloma1 item
  21. Non-small Cell Lung Cancer5item
  22. Ovarian Cancer1 item
  23. Pancreatic Cancer5item
  24. Prostate Cancer1 item
  25. Renal Cell Carcinoma1 item
  26. Rheumatoid Arthritis1 item
  27. Thyroid Cancer2item
  28. Type 2 Diabetes1 item